0001723128-26-000020
SEC filingQ1 2026 delivered robust profitability gains with gross profit up 25.1% and operating income rising 41.3%, driven by favorable revenue mix, manufacturing efficiencies, and lower amortization, despite modest 3.9% revenue growth and operating cash outflow.
Amneal Pharmaceuticals reported strong profitability improvements in Q1 FY2026, with gross profit increasing 25.1% to $320.1 million on $722.5 million of revenue. This expansion to a 44.3% gross margin was primarily due to the decrease in cost of goods sold from a favorable mix of revenues, including reduced low margin distribution sales, increased manufacturing efficiencies such as lower inventory obsolescence, and a reduction in amortization expense, partially offset by higher plant costs. These dynamics underscore the company's ability to leverage operational improvements to drive margin expansion even as revenue grew modestly by 3.9% year-over-year.
Net income reflected these gains, jumping 410.5% to $62.3 million, with diluted EPS rising to $0.19 from $0.04. The disproportionate profitability surge demonstrates effective cost management outweighing fixed expenses, enhancing shareholder value in a capital-intensive industry.
Operating cash flow shifted to an outflow of $26.7 million from an inflow of $7.4 million prior year, resulting in free cash flow of -$34.9 million after $8.2 million in capital expenditures, down from $13.2 million. The period-over-period increase in net cash used in investing activities stemmed primarily from higher deposits for future property, plant, and equipment acquisitions and intangible asset purchases, partially offset by lower capital expenditures. These investments signal commitment to growth initiatives, including planned borrowings for the Kashiv acquisition, which will elevate future interest expenses but support long-term capacity expansion.